Latest results from the COMPOSE® Phase 1/2 trial for the treatment of classical homocystinuria (HCU) using pegtibatinase, a novel investigational enzyme replacement therapy
Molecular Genetics and Metabolism（2024）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要